Paolo Tarantino, 2025 Yvonne’s “Top Voice” Award Winner, Clinical Research Fellow at Dana-Farber Cancer Institute, Visiting Professor at McGill University, shared a post on LinkedIn:
“We all remained jaw-open when we first saw the results from PATINA presented. They are now published in NEJM, and they remain astonishing.
Among patients with HR+/HER2+ metastatic breast cancer who remained progression-free after chemo induction, adding palbociclib to maintenace ET+HER2-blockade prolonged PFS from 29 to 44 months.
If you add the duration of induction chemo, this means 50 months (!!) only on first-line treatment, with dozens of active drugs remaining for second-line and beyond.
This is the closest we ever got to making metastatic breast cancer a chronic disease․ This raises tremendous hope for the treatment of a disease that unfortunately remains too prevalent — but which we are able to treat every day better.
Congrats to Otto Metzger and co-authors!”
Title: Palbociclib for Hormone-Receptor–Positive, HER2-Positive Advanced Breast Cancer
Authors: Otto Metzger, Sumithra Mandrekar, Shom Goel, Joseph Gligorov, Elgene Lim, Eva Ciruelos, Sibylle Loibl, Travis Dockter, Xavier Gonzàlez Farré, Prudence Francis, Filipa Lynce, Jane Lanzillotti, Carter DuFrane, Anna Wall, Carrie Strand, Ian Krop, Ines Vaz-Luis, Debu Tripathy, Sherene Loi, Aleix Prat, Matthew Goetz, Santiago Escrivá-de-Romaní, David Porter, Jennifer Spoenlein, Daniel Stover, Sagar Sardesai, Pierre Heudel, Maria Koehler, Cynthia Huang Bartlett, Ariadna Holynskyj, Prashanth Gopalakrishna, Eric Gauthier, Suzette Delaloge, Kathy Miller, Eric Winer, Luca Gianni, Ann Partridge, Angela DeMichele, Lisa Carey
Read the Full Article․
More posts featuring Paolo Tarantino.